Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort

Loreta A Kondili,Alberto Zanetto,Maria Giovanna Quaranta,Luigina Ferrigno,Valentina Panetta,Vincenza Calvaruso,Anna Linda Zignego,Maurizia R Brunetto,Giovanni Raimondo,Elisa Biliotti,Donatella Ieluzzi,Andrea Iannone,Salvatore Madonia,Liliana Chemello,Luisa Cavalletto,Carmine Coppola,Filomena Morisco,Francesco Barbaro,Anna Licata,Alessandro Federico,Federica Cerini,Marcello Persico,Maurizio Pompili,Alessia Ciancio,Fabio Piscaglia,Luchino Chessa,Andrea Giacometti,Pietro Invernizzi,Giuseppina Brancaccio,Antonio Benedetti,Leonardo Baiocchi,Ivan Gentile,Nicola Coppola,Gerardo Nardone,Antonio Craxì,Francesco Paolo Russo,PITER Collaborating Investigators,Monica Monti,Barbara Coco,Roberto Filomia,Erica Maria Bruno,Valentina Cossiga,Simona Amodeo,Marcello Dallio,Luciano Crapanzano,Mario Masarone,Martina De Siena,Ilaria Serio,Martina Loi,Lucia Brescini,Antonio Ciaccio,Monica Cucco,Xhimi Tata,Caterina Sagnelli,Costantino Sgamato,Ernesto Claar,Elena Rosselli Del Turco,Maria Grazia Rumi,Giovanni Battista Gaeta,Paolo Simioni
DOI: https://doi.org/10.1002/ueg2.12496
Abstract:Background & aims: Sustained virological response (SVR) by direct-acting antivirals (DAAs) may reverse the hypercoagulable state of HCV cirrhosis and the portal vein thrombosis (PVT) risk. We evaluated the incidence and predictive factors of de novo, non-tumoral PVT in patients with cirrhosis after HCV eradication. Methods: Patients with HCV-related cirrhosis, consecutively enrolled in the multi-center ongoing PITER cohort, who achieved the SVR using DAAs, were prospectively evaluated. Kaplan-Meier and competing risk regression analyses were performed. Results: During a median time of 38.3 months (IQR: 25.1-48.7 months) after the end of treatment (EOT), among 1609 SVR patients, 32 (2.0%) developed de novo PVT. A platelet count ≤120,000/μL, albumin levels ≤3.5 mg/dL, bilirubin >1.1 mg/dL, a previous liver decompensation, ALBI, Baveno, FIB-4, and RESIST scores were significantly different (p < 0.001), among patients who developed PVT versus those who did not. Considering death and liver transplantation as competing risk events, esophageal varices (subHR: 10.40; CI 95% 4.33-24.99) and pre-treatment ALBI grade ≥2 (subHR: 4.32; CI 95% 1.36-13.74) were independent predictors of PVT. After HCV eradication, a significant variation in PLT count, albumin, and bilirubin (p < 0.001) versus pre-treatment values was observed in patients who did not develop PVT, whereas no significant differences were observed in those who developed PVT (p > 0.05). After the EOT, esophageal varices and ALBI grade ≥2, remained associated with de novo PVT (subHR: 9.32; CI 95% 3.16-27.53 and subHR: 5.50; CI 95% 1.67-18.13, respectively). Conclusions: In patients with HCV-related cirrhosis, a more advanced liver disease and significant portal hypertension are independently associated with the de novo PVT risk after SVR.
What problem does this paper attempt to address?